Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate
Abstract BCG remains the only licensed vaccine for tuberculosis (TB), but its efficacy wanes over time. Subunit vaccines, aim to improve BCG immunity and protection, by inducing responses to a few mycobacterial antigens delivered with a specific platform. Since the platform shapes the immune respons...
Saved in:
Main Authors: | Marcellus Korompis, Christopher J De Voss, Shuailin Li, Alexandre Richard, Salem Salman Almujri, Alberta Ateere, Géraldine Frank, Céline Lemoine, Helen McShane, Elena Stylianou |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-84667-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I‐II pancreatic cancer
by: Sung Jun Ma, et al.
Published: (2019-03-01) -
The Effect of Adjuvant Therapy on Metabolic Syndrome in Schizophrenia Patients at Madani Hospital
by: Indah Kurnia Utami, et al.
Published: (2024-11-01) -
Vaccine adjuvants for immunotherapy: type, mechanisms and clinical applications
by: Nimeet Desai, et al.
Published: (2025-02-01) -
Transcriptional Systems Vaccinology Approaches for Vaccine Adjuvant Profiling
by: Diogo Pellegrina, et al.
Published: (2025-01-01) -
Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens
by: Chloé O. Sebilleau, et al.
Published: (2024-04-01)